Jim Cramer explains why young investors stand to benefit from the magic of compounding. » Read More
Jim Cramer offered up his best advice for investing at a young age. » Read More
Jim Cramer spelled out the importance of getting kids involved with investing at an early age. » Read More
David Einhorn is betting against one corporate stalwart and on another.
"Halftime Report" trader Joe Terranova bought shares of a pizza chain for his CNBC Pro model portfolio, which is currently up 13% on the year.
Some of the names on the move ahead of the open.
Dovish positioning from the Federal Reserve has been one of the many causes of mutual fund underperformance this year, JPMorgan finds.
Tesla met Wall Street's quarterly estimates and said it moved up its 500,000 unit build target by two years because of Model 3 demand.
"Fast Money" traders picked apart the bets made by noted stock pickers David Einhorn and Jim Chanos.
"I think he'll do a hell of a good job," Home Depot co-founder Ken Langone said of Donald Trump.
Jim Cramer dismissed Etsy as a hippy-dippy stock that would never be profitable. That all changed now, thanks to this amazing action.
Bond guru Jeff Gundlach discusses negative rates, Donald Trump and Apple in a wide-ranging interview from the sidelines of the Sohn Investment Conference.
Check out the companies making headlines after the bell Wednesday: Kraft Heinz, Tesla, Whole Foods and more.
Bad decisions have been made in the debt market that will ultimately lead to good investment opportunities, Howard Marks says.
Starboard Value is making a move against a pharmaceutical company it says is mismanaged, CEO Jeff Smith said Wednesday.
Zach Schreiber revealed his latest investment idea at the Sohn Investment Conference in New York Wednesday.
Priceline reported better-than-expected first-quarter earnings, yet the travel giant's stock was down nearly 9 percent.
Estimize looks at two Chinese companies whose earnings top expectations each quarter while maintaining an industry lead in the region.
Prominent hedge fund manager Larry Robbins spoke about his investment philosophy and what could be ahead for drug stocks.
Get the best of CNBC in your inbox